34 studies found for:    Cobicistat[TREATMENT] AND HIV [CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
Cobicistat[TREATMENT] AND HIV [CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Pharmacokinetics, Safety, and Efficacy of Cobicistat-boosted Atazanavir or Cobicistat-boosted Darunavir in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects
Conditions: Acquired Immune Deficiency Syndrome (AIDS);   HIV Infections
Interventions: Drug: ATV;   Drug: DRV;   Drug: Cobicistat;   Drug: BR
2 Active, not recruiting Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: Cobicistat;   Drug: Darunavir;   Drug: NRTI
3 Completed Bioequivalence (BE) Study of Individual Atazanavir and Cobicistat Compared to Atazanavir in Fixed Dose Combination With Cobicistat
Condition: Human Immunodeficiency Virus Type 1 (HIV-1)
Interventions: Drug: Atazanavir;   Drug: Cobicistat
4 Active, not recruiting Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: GS-9350 + atazanavir + emtricitabine/tenofovir DF;   Drug: Comparator: ritonavir + atazanavir + emtricitabine/tenofovir DF
5 Unknown  Safety and Efficacy of GS-9350-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Condition: HIV-1 Infection
Interventions: Drug: 150 mg tablet GS- 9350;   Drug: ritonavir 100 mg capsule;   Drug: atazanavir 300 mg capsule;   Drug: emtricitabine/tenofovir DF 200/300 mg tablet;   Drug: ritonavir placebo;   Drug: GS-9350 placebo
6 Completed Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: D/C/F/TAF;   Drug: DRV;   Drug: COBI;   Drug: FTC/TDF;   Drug: Placebo to match D/C/F/TAF;   Drug: Placebo to match DRV;   Drug: Placebo to match COBI;   Drug: Placebo to match FTC/TDF
7 Active, not recruiting Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: Placebo to match E/C/F/TDF;   Drug: Placebo to match E/C/F/TAF
8 Active, not recruiting Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF
9 Active, not recruiting Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV 1 Infected, Antiretroviral Treatment-Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: Placebo to match E/C/F/TAF;   Drug: Placebo to match E/C/F/TDF
10 Active, not recruiting Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF, EFV/FTC/TDF, ritonavir + atazanavir + FTC/TDF, or cobicistat + atazanavir + FTC/TDF
11 Not yet recruiting Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy
Condition: HIV Infection
Intervention: Drug: Treatment simplification
12 Active, not recruiting Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: EVG/COBI/FTC/TDF;   Drug: COBI;   Drug: ATV;   Drug: DRV;   Drug: NRTI
13 Not yet recruiting An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
Condition: HIV-2 Infection
Intervention: Drug: Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks
14 Active, not recruiting Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Conditions: HIV;   HIV Infections
Intervention: Drug: E/C/F/TAF
15 Recruiting Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
Conditions: HIV;   HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: TAF;   Drug: Placebo to match TAF;   Drug: E/C/F/TAF;   Drug: Pre-existing ARV regimen;   Drug: ATV
16 Recruiting Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Intervention: Drug: EVG/COBI/FTC/TDF
17 Recruiting Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
Conditions: HIV-1;   HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: E/C/F/TAF;   Drug: DRV;   Drug: Pre-existing ARV regimen
18 Active, not recruiting Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women (WAVES)
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: EVG/COBI/FTC/TDF;   Drug: RTV;   Drug: ATV;   Drug: FTC/TDF;   Drug: EVG/COBI/FTC/TDF Placebo;   Drug: RTV Placebo;   Drug: ATV Placebo;   Drug: FTC/TDF Placebo
19 Recruiting Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents
Conditions: Acquired Immune Deficiency Syndrome (AIDS);   HIV Infections
Intervention: Drug: E/C/F/TAF
20 Active, not recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: Stribild;   Drug: TVD;   Drug: NNRTI

Previous Page Studies Shown (1-20) Next Page (21-34) Show next page of results
Indicates status has not been verified in more than two years